Melisa Wong on Factors That Affect Lung Cancer Treatment

Tarlatamab, a bispecific T-cell engager, was approved by the FDA for adults with extensive-stage small cell lung cancer.

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Glecirasib resulted in durable responses with a manageable safety profile for pretreated advanced non-small cell lung cancer with KRAS G12C mutations.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Throughout April, the FDA approved drugs for the treatment of diseases including solid tumors, lung cancer, multiple myeloma, bladder cancer, and low-grade glioma.

Poor sleep quality among those with lung cancer and COPD emphasize the need to develop effective assessment strategies.